In US and Canada: For Research Use Only. Not for Use in Diagnostic Procedures.

BIOPHEN™ DiXaI is a two-stage chromogenic assay specifically designed for Direct oral FXa Inhibitors (DOACs) — rivaroxaban (XareltoŽ), apixaban (EliquisŽ), and edoxaban (SavaysaŽ/LixianaŽ) — in human citrated plasma. ?? NOT for heparins (UFH, LMWH), fondaparinux, or danaparoďd. For heparin monitoring, use BIOPHEN™ Heparin LRT instead. Two-stage method with constant exogenous AT (AT-independent — not affected by patient AT levels). Stage 1: patient DOAC + excess FXa + AT ? DOAC inhibits FXa. Stage 2: residual FXa measured with chromogenic substrate. Calibrators: Rivaroxaban (226001/226101/226201), Apixaban (226401/226501), Edoxaban (222701). Controls: drug-specific control plasmas at standard and low ranges. Dilution buffer: Tris-NaCl-EDTA pH 7.85 (AR032K). CE-IVD.